Wakefield Asset Management LLLP Boosts Position in Genomic Health, Inc. (GHDX)

Wakefield Asset Management LLLP boosted its stake in Genomic Health, Inc. (NASDAQ:GHDX) by 36.8% during the 1st quarter, HoldingsChannel reports. The fund owned 7,709 shares of the medical research company’s stock after acquiring an additional 2,074 shares during the quarter. Wakefield Asset Management LLLP’s holdings in Genomic Health were worth $540,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. TIAA CREF Investment Management LLC lifted its stake in shares of Genomic Health by 38.0% in the third quarter. TIAA CREF Investment Management LLC now owns 242,839 shares of the medical research company’s stock worth $17,052,000 after acquiring an additional 66,873 shares in the last quarter. Nordea Investment Management AB lifted its stake in shares of Genomic Health by 17.5% in the third quarter. Nordea Investment Management AB now owns 79,128 shares of the medical research company’s stock worth $5,557,000 after acquiring an additional 11,776 shares in the last quarter. Vanguard Group Inc. lifted its stake in shares of Genomic Health by 18.6% in the third quarter. Vanguard Group Inc. now owns 2,151,932 shares of the medical research company’s stock worth $151,109,000 after acquiring an additional 337,664 shares in the last quarter. Federated Investors Inc. PA lifted its stake in shares of Genomic Health by 12,387.3% in the third quarter. Federated Investors Inc. PA now owns 199,921 shares of the medical research company’s stock worth $14,039,000 after acquiring an additional 198,320 shares in the last quarter. Finally, JGP Global Gestao de Recursos Ltda. acquired a new position in shares of Genomic Health in the fourth quarter worth about $286,000. 91.80% of the stock is currently owned by institutional investors and hedge funds.

Several research firms recently commented on GHDX. ValuEngine cut Genomic Health from a “buy” rating to a “hold” rating in a research note on Wednesday, May 8th. Canaccord Genuity reiterated a “buy” rating and issued a $85.00 price target (down previously from $95.00) on shares of Genomic Health in a research note on Wednesday, May 8th. Zacks Investment Research cut Genomic Health from a “buy” rating to a “hold” rating in a research note on Tuesday, April 23rd. Needham & Company LLC reiterated a “strong-buy” rating and issued a $69.00 price target (down previously from $97.00) on shares of Genomic Health in a research note on Thursday, May 9th. Finally, BidaskClub cut Genomic Health from a “strong-buy” rating to a “buy” rating in a research note on Thursday, February 28th. Ten research analysts have rated the stock with a hold rating, one has issued a buy rating and one has issued a strong buy rating to the stock. Genomic Health presently has an average rating of “Hold” and a consensus target price of $63.71.

In other news, Director Bros. Advisors Lp Baker sold 600 shares of the company’s stock in a transaction that occurred on Thursday, February 28th. The stock was sold at an average price of $76.20, for a total transaction of $45,720.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Kimberly J. Popovits sold 47,900 shares of the company’s stock in a transaction that occurred on Thursday, February 14th. The shares were sold at an average price of $81.70, for a total value of $3,913,430.00. The disclosure for this sale can be found here. Insiders have sold 1,523,292 shares of company stock worth $110,322,276 in the last 90 days. 31.30% of the stock is currently owned by insiders.

Shares of NASDAQ GHDX opened at $57.36 on Wednesday. Genomic Health, Inc. has a 52-week low of $36.94 and a 52-week high of $92.18. The company has a market cap of $2.11 billion, a price-to-earnings ratio of 54.63 and a beta of 0.88. The company has a debt-to-equity ratio of 0.19, a quick ratio of 5.67 and a current ratio of 5.67.

Genomic Health (NASDAQ:GHDX) last announced its quarterly earnings data on Tuesday, May 7th. The medical research company reported $0.34 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.29 by $0.05. Genomic Health had a return on equity of 18.70% and a net margin of 10.35%. The firm had revenue of $108.80 million for the quarter, compared to analysts’ expectations of $106.75 million. During the same quarter in the prior year, the firm posted ($0.11) earnings per share. Genomic Health’s revenue for the quarter was up 17.5% compared to the same quarter last year. As a group, equities research analysts predict that Genomic Health, Inc. will post 1.46 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Wakefield Asset Management LLLP Boosts Position in Genomic Health, Inc. (GHDX)” was originally published by Baseball Daily News and is the sole property of of Baseball Daily News. If you are reading this article on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The legal version of this article can be read at https://www.baseballdailydigest.com/news/2019/05/15/wakefield-asset-management-lllp-boosts-position-in-genomic-health-inc-ghdx.html.

Genomic Health Company Profile

Genomic Health, Inc, a healthcare company, provides clinically actionable genomic information to personalize cancer treatment decisions in the United States and internationally. The company develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, which allows physicians and patients to make individualized treatment decisions.

Featured Article: What are the benefits of investing in REITs?

Want to see what other hedge funds are holding GHDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Genomic Health, Inc. (NASDAQ:GHDX).

Institutional Ownership by Quarter for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.